Treatment of Osteoporosis after Hip Fracture: Survey of the Korean Hip Society

키워드

참고문헌 (50)

1. Ahn SH, "Osteoporosis and osteoporotic fracture fact sheet in Korea", J Bone Metab, 27, pp.281~290 (2020)[DOI]
2. Oh YK, "Management of osteoporosis medication after osteoporotic fracture", Hip Pelvis, 34, pp.191~202 (2022)[DOI]
3. Castel H, "Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures", Osteoporos Int, 12, pp.559~564 (2001)[DOI]
4. Freedman KB, "Treatment of osteoporosis : are physicians missing an opportunity?", J Bone Joint Surg Am, 82, pp.1063~1070 (2000)[DOI]
5. Gardner MJ, "Improvement in the undertreatment of osteoporosis following hip fracture", J Bone Joint Surg Am, 84, pp.1342~1348 (2002)[DOI]
6. Jin YZ, "Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events : a meta-analysis of randomized controlled trials", BMC Musculoskelet Disord, 20, pp.399~ (2019)[DOI]
7. Kim SR, "Orthopedic surgeon's awareness can improve osteoporosis treatment following hip fracture : a prospective cohort study", J Korean Med Sci, 26, pp.1501~1507 (2011)[DOI]
8. Barker KL, "A qualitative systematic review of patients' experience of osteoporosis using meta-ethnography", Arch Osteoporos, 11, pp.33~ (2016)[DOI]
9. Edwards BJ, "Postmenopausal women with minimal trauma fractures are unapprised of the existence of low bone mass or osteoporosis", Maturitas, 53, pp.260~266 (2006)[DOI]
10. Feldstein AC, "Harnessing stakeholder perspectives to improve the care of osteoporosis after a fracture", Osteoporos Int, 19, pp.1527~1540 (2008)[DOI]
11. Haaland DA, "Closing the osteoporosis care gap : increased osteoporosis awareness among geriatrics and rehabilitation teams", BMC Geriatr, 9, pp.28~ (2009)[DOI]
12. Oumer KS, "Awareness of osteoporosis among 368 residents in China : a cross-sectional study", BMC Musculoskelet Disord, 21, pp.197~ (2020)[DOI]
13. Silverstein WK, "Closing the osteoporosis care gap : a teachable moment", JAMA Intern Med, 181, pp.1635~1636 (2021)[DOI]
14. Bergmann P, "Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis : a consensus document of the Belgian Bone Club", Int J Clin Pract, 63, pp.19~26 (2009)[DOI]
15. Vasikaran S, "International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis", Clin Chem Lab Med, 49, pp.1271~1274 (2011)[DOI]
16. Aspray TJ, "National Osteoporosis Society vitamin D guideline summary", Age Ageing, 43, pp.592~595 (2014)[DOI]
17. Weaver CM, "Calcium plus vitamin D supplementation and risk of fractures : an updated meta-analysis from the National Osteoporosis Foundation", Osteoporos Int, 27, pp.367~376 (2016)[DOI]
18. Bolland MJ, "Effects of vitamin D supplementation on musculoskeletal health : a systematic review, meta-analysis, and trial sequential analysis", Lancet Diabetes Endocrinol, 6, pp.847~858 (2018)[DOI]
19. Smith LM, "Effect of increasing doses of vitamin D on bone mineral density and serum N-terminal telopeptide in elderly women : a randomized controlled trial", J Intern Med, 284, pp.685~693 (2018)[DOI]
20. Grant AM, "Oral vitamin D3and calcium for secondary prevention of low-trauma fractures in elderly people(Randomised Evaluation of Calcium Or vitamin D, RECORD) : a randomised placebo-controlled trial", Lancet, 365, pp.1621~1628 (2005)[DOI]
21. Khaw KT, "Effect of monthly high-dose vitamin D supplementation on falls and nonvertebral fractures : secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial", Lancet Diabetes Endocrinol, 5, pp.438~447 (2017)[DOI]
22. Bordelon P, "Recognition and management of vitamin D deficiency", Am Fam Physician, 80, pp.841~846 (2009)
23. Ringe JD, "Plain vitamin D or active vitamin D in the treatment of osteoporosis : where do we stand today?", Arch Osteoporos, 15, pp.182~ (2020)[DOI]
24. Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med, 361, pp.756~765 (2009)[DOI]
25. Brown JP, "Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass : a randomized, blinded, phase 3 trial", J Bone Miner Res, 24, pp.153~161 (2009)[DOI]
26. Bone HG, "10 years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5, pp.513~523 (2017)[DOI]
27. Watts NB, "Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years", J Clin Endocrinol Metab, 104, pp.2443~2452 (2019)[DOI]
28. Bone HG, "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass", J Clin Endocrinol Metab, 96, pp.972~980 (2011)[DOI]
29. Miller PD, "Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy : a randomized blinded phase 2 clinical trial", Bone, 43, pp.222~229 (2008)[DOI]
30. McClung MR, "Cancel the denosumab holiday", Osteoporos Int, 27, pp.1677~1682 (2016)[DOI]
31. Kendler DL, "Denosumab in the treatment of osteoporosis : 10 years later : a narrative review", Adv Ther, 39, pp.58~74 (2022)[DOI]
32. Chen LP, "The correlation between lateral bowing angle of the femur and the location of atypical femur fractures", Calcif Tissue Int, 95, pp.240~247 (2014)[DOI]
33. Oh Y, "Biological activity is not suppressed in mid-shaft stress fracture of the bowed femoral shaft unlike in"typical"atypical subtrochanteric femoral fracture : a proposed theory of atypical femoral fracture subtypes", Bone, 137, pp.115453~ (2020)[DOI]
34. Park YC, "Localization of atypical femoral fracture on straight and bowed femurs", J Bone Metab, 26, pp.123~131 (2019)[DOI]
35. Soh HH, "Atypical fractures of the femur : effect of anterolateral bowing of the femur on fracture location", Arch Orthop Trauma Surg, 135, pp.1485~1490 (2015)[DOI]
36. Takakubo Y, "Differences in subtrochanteric and diaphyseal atypical femoral fractures in a super-aging prefectural area : YamaCAFe Study", J Bone Miner Metab, 39, pp.700~711 (2021)[DOI]
37. Bernhard A, "Micromorphological properties of osteons reveal changes in cortical bone stability during aging, osteoporosis, and bisphosphonate treatment in women", Osteoporos Int, 24, pp.2671~2680 (2013)[DOI]
38. Milovanovic P, "Multilevel characterization of human femoral cortices and their underlying osteocyte network reveal trends in quality of young, aged, osteoporotic and antiresorptive-treated bone", Biomaterials, 45, pp.46~55 (2015)[DOI]
39. Zimmermann EA, "Intrinsic mechanical behavior of femoral cortical bone in young, osteoporotic and bisphosphonate-treated individuals in lowand high energy fracture conditions", Sci Rep, 6, pp.21072~ (2016)[DOI]
40. Lim SJ, "Incidence, risk factors, and fracture healing of atypical femoral fractures : a multicenter casecontrol study", Osteoporos Int, 29, pp.2427~2435 (2018)[DOI]
41. Hyodo K, "Location of fractures and the characteristics of patients with atypical femoral fractures : analyses of 38 Japanese cases", J Bone Miner Metab, 35, pp.209~214 (2017)[DOI]
42. Schneider PS, "Atypical femur fractures : a survey of current practices in orthopedic surgery", Osteoporos Int, 28, pp.3271~3276 (2017)[DOI]
43. Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures : second report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 29, pp.1~23 (2014)[DOI]
44. Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 25, pp.2267~2294 (2010)[DOI]
45. Schilcher J, "Bisphosphonate use and atypical fractures of the femoral shaft", N Engl J Med, 364, pp.1728~1737 (2011)[DOI]
46. Byun SE, "The effect of teriparatide on fracture healing after atypical femoral fracture : a systematic review and meta-analysis", Osteoporos Int, 34, pp.1323~1334 (2023)[DOI]
47. Langdahl BL, "Romosozumab(sclerostin monoclonal antibody)versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy : a randomised, open-label, phase 3 trial", Lancet, 390, pp.1585~1594 (2017)[DOI]
48. Obermayer-Pietsch BM, "Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment", J Bone Miner Res, 23, pp.1591~1600 (2008)[DOI]
49. Adler RA, "Managing osteoporosis in patients on long-term bisphosphonate treatment : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 31, pp.16~35 (2016)[DOI]
50. Dell R, "A proposal for an atypical femur fracture treatment and prevention clinical practice guideline", Osteoporos Int, 29, pp.1277~1283 (2018)[DOI]

관련 논문AI추천